As of 2021, in Japan, anti-VEGF drugs are administered intravitreally for AMD with subcentral foveal CNV, macular edema associated with retinal vein occlusion, CNV in pathologic myopia, neovascular glaucoma, and retinopathy of prematurity. This evidence concerns the gene VEGFA and age-related macular degeneration.